Enovis Corp (ENOV) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Enovis Corp stock (ENOV) is currently trading at $22.62. Enovis Corp PS ratio (Price-to-Sales) is 0.56. Analyst consensus price target for ENOV is $45.18. WallStSmart rates ENOV as Hold.
- ENOV PE ratio analysis and historical PE chart
- ENOV PS ratio (Price-to-Sales) history and trend
- ENOV intrinsic value — DCF, Graham Number, EPV models
- ENOV stock price prediction 2025 2026 2027 2028 2029 2030
- ENOV fair value vs current price
- ENOV insider transactions and insider buying
- Is ENOV undervalued or overvalued?
- Enovis Corp financial analysis — revenue, earnings, cash flow
- ENOV Piotroski F-Score and Altman Z-Score
- ENOV analyst price target and Smart Rating
Enovis Corp
📊 No data available
Try selecting a different time range
Smart Analysis
Enovis Corp (ENOV) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, eps growth. Concerns around return on equity and operating margin. Fundamentals are solid but monitor weak areas for improvement.
Enovis Corp (ENOV) Key Strengths (4)
Paying less than $1 for every $1 of annual revenue
Trading below book value, meaning the market prices it less than net assets
Earnings per share surging 153.10% year-over-year
117.95% of shares held by major funds and institutions
Supporting Valuation Data
Enovis Corp (ENOV) Areas to Watch (6)
Company is destroying shareholder value
Company is losing money with a negative profit margin
Very thin margins with limited operational efficiency
Revenue growing slowly at 2.60% annually
Small-cap company with higher risk but more growth potential
Growth is fairly priced, not cheap, not expensive
Enovis Corp (ENOV) Detailed Analysis Report
Overall Assessment
This company scores 56/100 in our Smart Analysis, earning a C grade. Out of 10 metrics analyzed, 4 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 2.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Price/Book, EPS Growth. Valuation metrics including Price/Sales (0.56), Price/Book (0.84) suggest the stock is attractively priced. Growth metrics are encouraging with EPS Growth at 153.10%.
The Bear Case
The primary concerns are Return on Equity, Profit Margin, Operating Margin. Some valuation metrics including PEG Ratio (1.90) suggest expensive pricing. Growth concerns include Revenue Growth at 2.60%, which may limit upside. Profitability pressure is visible in Return on Equity at -58.30%, Operating Margin at 6.09%, Profit Margin at -52.70%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -58.30% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 2.60% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Price/Sales, Price/Book) and negatives (Return on Equity, Profit Margin). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ENOV Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ENOV's Price-to-Sales ratio of 0.56x trades 46% below its historical average of 1.04x (22th percentile). The current valuation is 81% below its historical high of 2.91x set in Mar 2012, and 88% above its historical low of 0.3x in Mar 2020. Over the past 12 months, the PS ratio has compressed from ~1.0x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Enovis Corp (ENOV) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Enovis Corp is in a turnaround phase, with management focused on restoring profitability. Revenue reached 2.2B with 3% growth year-over-year. The company is currently unprofitable, posting a -52.7% profit margin.
Key Findings
Generating 32M in free cash flow and 89M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -52.7% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Volatility is elevated with a beta of 1.60, so expect amplified moves relative to the broader market.
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Enovis Corp.
Bottom Line
Enovis Corp is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(37 last 3 months)
| Insider | Type | Shares |
|---|---|---|
ENGERT, OLIVER Chief Administrative Officer | Buy | +1,000 |
| Insider | Type | Shares |
|---|---|---|
ENGERT, OLIVER Chief Administrative Officer | Buy | +1,000 |
| Insider | Type | Shares |
|---|---|---|
ENGERT, OLIVER Chief Administrative Officer | Buy | +1,000 |
| Insider | Type | Shares |
|---|---|---|
ENGERT, OLIVER Chief Administrative Officer | Buy | +1,000 |
| Insider | Type | Shares |
|---|---|---|
ENGERT, OLIVER Chief Administrative Officer | Buy | +42,640 |
| Insider | Type | Shares |
|---|---|---|
LALOR, ANGELA S Director | Buy | +845 |
Data sourced from SEC Form 4 filings
Last updated: 11:34:23 AM
About Enovis Corp(ENOV)
NYSE
HEALTHCARE
MEDICAL DEVICES
USA
Enovis Corporation is a global medical technology company. The company is headquartered in Wilmington, Delaware.